Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion Pharmaceuticals reports fourth-quarter and full-year 2025 results Wednesday before the market opens, with investors scrutinizing whether the AI-driven biotech can translate its massive data ...

Strategic collaboration explores manufacturing infrastructure for Solstice™, a high energy density, solid-state platform designed for extended range and high temperature stability BOSTON & SEOUL, ...

Objectives To compare the clinical effectiveness of (1) physiotherapist-led exercise versus an exercise leaflet, and (2) ultrasound-guided subacromial corticosteroid injection versus unguided ...

The pharmaceutical market, worth $1.7 trillion, offers stable long-term investment opportunities. Top pharma stocks like AbbVie and Pfizer are poised for growth despite patent challenges. Invest in ...